Effect of tumor morcellation in patients with early uterine sarcoma: a multicenter study in Germany

George Gitas, Kubilay Ertan, Sascha Baum, Achim Rody, George Pados, Kristina Wihlfahrt, Christos Kotanidis, Leila Allahqoli, Antonio Simone Laganà, Soteris Sommer, Ibrahim Alkatout
Author Information
  1. George Gitas: Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Luebeck, Luebeck, Germany ORCID
  2. Kubilay Ertan: Department of Obstetrics and Gynecology, Municipal Hospital of Leverkusen, Leverkusen, Germany ORCID
  3. Sascha Baum: Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Luebeck, Luebeck, Germany ORCID
  4. Achim Rody: Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Luebeck, Luebeck, Germany ORCID
  5. George Pados: Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece ORCID
  6. Kristina Wihlfahrt: Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany ORCID
  7. Christos Kotanidis: Department of Obstetrics and Gynecology, Vivantes Humboldt, Berlin, Germany ORCID
  8. Leila Allahqoli: Ministry of Health and Medical Education, Tehran, Iran ORCID
  9. Antonio Simone Laganà: Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy ORCID
  10. Soteris Sommer: Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Luebeck, Luebeck, Germany ORCID
  11. Ibrahim Alkatout: Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany ORCID

Abstract

Objective: The use of power morcellation at laparoscopy may worsen survival rates for patients with malignancy. The aim of the present study was to report the outcome of patients with early-stage uterine sarcoma after morcellation or total en-bloc resection, and evaluate potential signs of sarcoma preoperatively.
Material and Methods: This multicenter retrospective study consisted of patients, who underwent surgery for FIGO-stage-1 uterine sarcoma. Twenty-four patients were divided into a non-morcellation group and a morcellation group. Clinical records and the outcomes of patients, including one-, three- and five-year survival rates were reviewed. Preoperative characteristics of patients with sarcoma were compared to those of a control group with uterine myoma (1:4 ratio), matched by age and type of operation.
Results: Obesity was an independent risk factor for uterine myoma. Tumor growth, solitary growth, largest-diameter lesion >8.0 cm, and anechoic areas suggesting necrosis and increased vascularization were significantly more common in the sarcoma group. A large tumor diameter was significantly associated with mortality. Patients in the non-morcellation group had a slightly lower disease-free survival, but poorer overall survival (OS) rates compared to patients in the morcellation group, but neither difference was statistically significant. Patients in the non-morcellation group, who had undergone a re-exploration experienced late recurrence, but no upstaging was evident after the operation.
Conclusion: Preoperative ultrasound characteristics could be useful to distinguish sarcoma from leiomyoma of uterus. Morcellation of a sarcoma may increase abdominal and pelvic recurrence rates, but may not be associated with OS in patients with FIGO-stage-1 disease.

Keywords

References

  1. Minerva Ginecol. 2017 Dec;69(6):517-525 [PMID: 28696085]
  2. Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):681-9 [PMID: 21816678]
  3. Cochrane Database Syst Rev. 2018 Oct 31;10:CD006655 [PMID: 30379327]
  4. Arch Gynecol Obstet. 2020 Aug;302(2):447-453 [PMID: 32488399]
  5. Gynecol Oncol. 2015 Apr;137(1):167-72 [PMID: 25462199]
  6. Gynecol Minim Invasive Ther. 2018 Apr-Jun;7(2):47-55 [PMID: 30254937]
  7. J Obes. 2013;2013:291546 [PMID: 24073332]
  8. J Minim Invasive Gynecol. 2015 Jan;22(1):26-33 [PMID: 25193444]
  9. J Cancer Res Clin Oncol. 2009 Oct;135(10):1387-91 [PMID: 19363622]
  10. Gynecol Oncol. 2008 Jul;110(1):43-8 [PMID: 18445505]
  11. Int J Gynecol Cancer. 2008 Mar-Apr;18(2):352-6 [PMID: 18334013]
  12. Pathologe. 2009 Jul;30(4):302-3 [PMID: 19513716]
  13. Cancer. 2012 Feb 1;118(3):660-9 [PMID: 21751199]
  14. Minim Invasive Ther Allied Technol. 2022 Jan;31(1):13-23 [PMID: 32491929]
  15. Arch Pathol Lab Med. 2000 Oct;124(10):1448-53 [PMID: 11035573]
  16. Int J Gynecol Cancer. 2013 Jul;23(6):1036-43 [PMID: 23714705]
  17. Gynecol Oncol. 2011 Aug;122(2):255-9 [PMID: 21565389]
  18. J Med Case Rep. 2019 Oct 27;13(1):319 [PMID: 31655625]
  19. Gynecol Oncol. 2012 Jan;124(1):172-3; author reply 173 [PMID: 21955481]
  20. Cancer. 2014 Oct 15;120(20):3154-8 [PMID: 24923260]
  21. Hum Reprod. 2017 Oct 1;32(10):2036-2041 [PMID: 28938732]
  22. Int J Gynecol Cancer. 2013 Jun;23(5):869-76 [PMID: 23669444]
  23. J Turk Ger Gynecol Assoc. 2017 Dec 15;18(4):221-223 [PMID: 29278237]
  24. J Obstet Gynaecol Res. 2016 Mar;42(3):313-8 [PMID: 26695124]
  25. Obstet Gynecol. 2016 Jan;127(1):29-39 [PMID: 26646120]
  26. J Clin Ultrasound. 2007 Oct;35(8):449-57 [PMID: 17636502]
  27. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1065-70 [PMID: 17986239]
  28. Lancet Oncol. 2009 Dec;10(12):1188-98 [PMID: 19959075]
  29. Arch Gynecol Obstet. 2019 Jul;300(1):169-174 [PMID: 31006842]
  30. Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [PMID: 8381710]
  31. J Obstet Gynaecol Can. 2017 Aug;39(8):652-658 [PMID: 28729098]
  32. Taiwan J Obstet Gynecol. 2015 Apr;54(2):172-7 [PMID: 25951723]
  33. Maturitas. 2012 May;72(1):56-60 [PMID: 22377186]
  34. Int J Gynecol Cancer. 2009 Feb;19(2):257-60 [PMID: 19396005]

Word Cloud

Created with Highcharts 10.0.0patientssarcomagroupmorcellationsurvivaluterineratesmaystudynon-morcellationlaparoscopymalignancymulticenterFIGO-stage-1PreoperativecharacteristicscomparedmyomaoperationgrowthsignificantlytumorassociatedPatientsOSrecurrenceObjective:usepowerworsenaimpresentreportoutcomeearly-stagetotalen-blocresectionevaluatepotentialsignspreoperativelyMaterialMethods:retrospectiveconsistedunderwentsurgeryTwenty-fourdividedClinicalrecordsoutcomesincludingone-three-five-yearreviewedcontrol1:4ratiomatchedagetypeResults:ObesityindependentriskfactorTumorsolitarylargest-diameterlesion>80cmanechoicareassuggestingnecrosisincreasedvascularizationcommonlargediametermortalityslightlylowerdisease-freepooreroverallneitherdifferencestatisticallysignificantundergonere-explorationexperiencedlateupstagingevidentConclusion:ultrasoundusefuldistinguishleiomyomauterusMorcellationincreaseabdominalpelvicdiseaseEffectearlysarcoma:GermanyMorcellationunexpectedrate

Similar Articles

Cited By